PT - JOURNAL ARTICLE AU - Malagón, Talía AU - Trottier, Helen AU - El-Zein, Mariam AU - Villa, Luisa L AU - Franco, Eduardo AU - , TI - Human papillomavirus intermittence, redetections, and associated risk of cytological abnormalities in the Ludwig-McGill cohort study of adult women AID - 10.1101/2022.10.12.22280699 DP - 2022 Jan 01 TA - medRxiv PG - 2022.10.12.22280699 4099 - http://medrxiv.org/content/early/2022/10/13/2022.10.12.22280699.short 4100 - http://medrxiv.org/content/early/2022/10/13/2022.10.12.22280699.full AB - Introduction We assessed the incidence of redetection with the same human papillomavirus (HPV) genotype, predictors of first HPV detections and redetections, and prevalence of cytological lesions during HPV redetections.Methods The Ludwig-McGill cohort study followed women aged 18-60 years from São Paulo, Brazil in 1993-1997 for up to 10 years. Women provided cervical samples for cytology testing and HPV DNA testing at each visit. A redetection was defined as a recurring genotype-specific HPV positive result after one or more intervening negative visits. Predictors of genotype-specific redetection were assessed using adjusted hazard ratios (aHR) with Cox regression modeling.Results 2184 women contributed 2368 incident HPV genotype-specific first detections and 308 genotype-specific redetections over a median follow-up of 6.5 years. The cumulative incidence of redetection with the same genotype was 7% at 1 year and 15% at 5 years after the loss of positivity of the first detection. Neither age (aHR 0.90, 95%CI 0.54-1.47 for ≥45y vs. <25y) nor new sexual partner acquisition (aHR 0.98, 95%CI 0.70-1.35) were statistically associated with genotype-specific redetection. High-grade squamous intraepithelial lesion prevalence was similar during first HPV detections (2.9%) and redetection (3.2%).Conclusions Our findings suggest many HPV redetections were likely reactivations of latent recurring infections.Competing Interest StatementTM has no conflicts of interest to declare. HT reports grants to her institution from CIHR and occasional lecture fees from Merck. LLV reports grants from Merck & Co. and personal fees from Merck & Co. outside the submitted work. ELF reports grants to his institution from CIHR and the National Institutes of Health during the conduct of the study; and personal fees from Merck. MZ and ELF hold a patent related to the discovery "DNA methylation markers for early detection of cervical cancer", registered at the Office of Innovation and Partnerships, McGill University, Montreal, Quebec, Canada.Clinical Protocols https://doi.org/10.1590/s1020-49891999000900001 Funding StatementThis work was supported by an intramural grant from the Ludwig Institute for Cancer Research (to LLV and ELF); the U.S. National Cancer Institute (CA70269 to ELF); the Canadian Institutes of Health Research (grants MA-13647, MOP-49396, CRN-83320 to ELF); a salary award from the Fonds de la recherche du Québec en santé to HT; and a new investigator salary award from the Canadian Institutes of Health Research to HT. The funders of the study had no involvement in study design; in the collection, analysis, and interpretation of data; neither in the writing of the report; and in the decision to submit the article. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of McGill University (Montreal, Canada) gave ethical approval for this work Ethics committee/IRB of University of Toronto (Toronto, Canada) gave ethical approval for this work Ethics committee/IRB of Ludwig Institute for Cancer Research (São Paulo, Brazil) gave ethical approval for this work Ethics committee/IRB of Maternidade Escola Dr. Mario de Moraes Altenfelder Silva Municipal Hospital clinic (São Paulo, Brazil) gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesParticipants of the Ludwig-McGill cohort study did not consent to have their data made publicly available, and confidentiality precludes the publishing of their data. To access the data for research purposes, please contact Eduardo Franco (eduardo.franco@mcgill.ca) or Luisa Villa (l.villa@hc.fm.usp.br). The program code for the current results is available at the McGill University Dataverse repository: https://doi.org/10.5683/SP3/EIF6A7. https://doi.org/10.5683/SP3/EIF6A7